Navigation Links
Deep sequencing of breast cancer tumors to predict clinical outcomes after single dose of therapy
Date:12/12/2013

CLEVELAND: New research from University Hospitals (UH) Case Medical Center Seidman Cancer Center and Case Comprehensive Cancer Center at Case Western Reserve University examined how changes in the genetic composition of breast cancer tumors after brief exposure to either biologic therapy or chemotherapy can predict future clinical outcomes in patients.

Results showed that through deep genome sequencing, a reduction in the most commonly mutated genes in breast cancer could be observed after just one dose of preoperative therapy. Deep sequencing is a process that involves sequencing the same region multiple times to identify mutations within tumors that have an importance in cancer evolution. These new findings were presented during the 2013 San Antonio Breast Cancer Symposium.

"Genomics is the new frontier of cancer research, and this study shows that we may be able to accurately determine what treatment methods will and will not be effective for individual patients after just one dose of medicine," said Lyndsay Harris, MD, study investigator and Director, Breast Cancer Program, UH Seidman Cancer Center and Professor of Medicine at Case Western Reserve University School of Medicine. "The ability to understand potential clinical outcomes for patients earlier in the treatment process would provide physicians with better opportunity to personalize patients' medicines according to their own tumor responses."

More than 209,000 patients in the U.S. are diagnosed with breast cancer each year. The anticipated outcome of studying the genetic makeup of breast cancer patients is to determine who will benefit most from certain drug therapies and to use that information to create a personalized treatment plan for each patient involved. Dr. Harris and team are currently integrating whole genome profiles with deep sequencing data as they spearhead a new study at UH Seidman Cancer Center to validate these initial findings presented in San Antonio.

Dr. Harris' co-presenters are: Nicole Williams, Vinay Varadan, Kristy Miskimen, Aditi Vadodkar, Debora Poruban,, Simone Edelheit, Hannah Gilmore, Steve Maximuk, Natalie Sinclair, Kimberly Lezon-Geyda, Maysa Abu-Khalaf, William Sikov, University Hospitals Case Medical Center/Case Western Reserve University, Cleveland, OH; Yale University School of Medicine; Yale Comprehensive Cancer Center, New Haven, CT; Warren Alpert Medical School of Brown, Providence, RI.

About the Studies

P1-08-16: Poster Session 1: Prognosis and Response Prediction: Response Predictive Factors
Deep sequencing of breast tumor biopsies reveals an association between pathologic complete response (pCR) and reduction of TP53 clonal abundance upon brief exposure to therapy
Wednesday 12/11, 5:00 PM -7:00 PM

Investigators evaluated 120 Stage IIA to IIIB breast cancer patients and compared a first biopsy after brief exposure to either biologic or chemotherapy treatment with a second biopsy taken after surgery. Researchers utilized deep genomic sequencing to quantify the abundance of clonal mutations in breast core biopsies, assess changes in these mutations after brief exposure to a targeted therapy and then evaluate the corresponding change in abundance of these mutations after exposure. This process of quantifying and monitoring clonal mutations between initial therapy exposure and surgery allowed researchers to determine how changes in the abundance of these mutations related to a patient's response to preoperative therapy. Through this analysis, investigators determined that clonal abundance upon brief exposure to therapy may be associated with clinical outcomes.


'/>"/>

Contact: Alicia Reale
alicia.reale@uhhospitals.org
216-844-5158
University Hospitals Case Medical Center
Source:Eurekalert

Related biology news :

1. Powerful sequencing technology decodes DNA folding pattern
2. Sequencing works in clinical setting to help -- finally -- get a diagnosis
3. The sequencing of the tomato genome
4. DNA Sequencing: Emerging Technologies and Applications
5. Next-generation sequencing technology opens doors to discoveries
6. University of North Texas Health Science Center Advances Forensic Research by Investing in Semiconductor DNA Sequencing Technology
7. Exome sequencing gives cheaper, faster diagnosis in heterogeneous disease
8. An error-eliminating fix overcomes big problem in 3rd-gen genome sequencing
9. Exome sequencing of health condition extremes can reveal susceptibility genes
10. New genomic sequencing method enables smarter anaysis of individual cells
11. US-Russian collaboration develops new method for sequencing dark matter of life from a single cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... and ITHACA, N.Y. , ... and Cornell University, a leader in dairy research, today ... bioinformatics designed to help reduce the chances that the ... the onset of this dairy project, Cornell University has ... for Sequencing the Food Supply Chain, a food safety ...
(Date:5/23/2017)... first robotic gym for the rehabilitation and functional motor sense evaluation of ... Italy . The first 30 robots will be available from June ... . The technology was developed and patented at the IIT laboratories and ... thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:5/16/2017)... May 16, 2017   Bridge Patient Portal ... and MD EMR Systems , an electronic ... for GE, have established a partnership to build ... and the GE Centricity™ products, including Centricity Practice ... These new integrations will allow healthcare ...
Breaking Biology News(10 mins):
(Date:8/16/2017)... edition of the Inc. 5000 features a now-familiar name: BioPoint ( http://biopointinc.com/ ... list for the third year in a row. Now in its 36th ... a set of quantitative metrics. In addition, BioPoint was also named to ... Bay State . ... ...
(Date:8/15/2017)... ... August 15, 2017 , ... Nanomedical Diagnostics , ... development, announces the launch of the new NHS Agile biosensor chip . ... data for a wide range of molecules, including small and large molecules, peptides, ...
(Date:8/15/2017)... ... August 15, 2017 , ... The Conference Forum ... Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and events. The partnership ... 2018, at The Roosevelt Hotel in New York City. , “With our experience in ...
(Date:8/14/2017)... Oregon (PRWEB) , ... August 14, 2017 , ... ... that provide essential device-to-computer interconnect using USB or PCI Express, announced the release ... , SYZYGY is intended to satisfy the need for a compact, low cost, ...
Breaking Biology Technology: